Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash,
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the
PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
DENVER, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The small-cap market is heating up as earnings acceleration, AI adoption, defense technology and government opportunities create a fresh wave of catalysts. CorMedix
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital Markets
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on
– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations and drug-drug
PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and
